SLSomchai Leelakusolvong

Somchai Leelakusolvong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Somchai Leelakusolvong has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Helicobacter pylori Management in ASEAN Countries: The Bangkok II Consensus Report

    by Ratha‐Korn Vilaichone, Duc Trong Quach, Phubordee Bongkotvirawan, Yeong Yeh Lee, Tiing‐Leong Ang, Muhammad Miftahussurur, Ari Fahrial Syam, Rona Marie Lawenko, Than Than Aye, Sengdao Vannarath, et al.

    Background and Aim: Helicobacter pylori infection remains a major cause of gastric cancer, peptic ulcer disease, and dyspepsia‐related morbidity across ASEAN. Since the first Bangkok Consensus Report in 2018, major advances have emerged in epidemiology, antimicrobial resistance, diagnostics, and eradication therapy. The Bangkok II Consensus Report aimed to provide updated evidence‐based recommendations tailored to Southeast Asia. Methods: A multidisciplinary panel from ASEAN and international partner countries updated regional guidance through three working groups covering epidemiology and indications for treatment, diagnostic testing and confirmation of eradication, and treatment strategies. Clinical questions and statements were developed from structured evidence review. Evidence quality and recommendation strength were graded using GRADE, with consensus defined as ≥ 80% agreement. Results: Twenty‐one clinical questions were addressed. The consensus emphasizes that H. pylori remains an important public health problem in ASEAN; eradication is central to gastric cancer prevention and ulcer management; diagnostic tests should be selected according to indication and local availability; 14‐day bismuth quadruple therapy is the preferred empirical first‐line regimen because of high clarithromycin resistance; PCAB‐based regimens are promising alternatives; and posttreatment confirmation of eradication should be routinely performed. Conclusions: The Bangkok II Consensus Report provides regionally relevant recommendations integrating antimicrobial resistance, healthcare disparities, and resource‐adapted strategies across ASEAN, addressing gaps in global guidelines and supporting reduction of H. pylori ‐associated disease, including gastric cancer, across Southeast Asia.

  • Open Access

    Anterior versus posterior peroral endoscopic myotomy: a prospective randomized controlled trial from a Thai tertiary center

    by Tharathorn Suwatthanarak, Siwaree Maneesoi, Chatbadin Thongchuam, Thawatchai Akaraviputh, Vitoon Chinswangwatanakul, Somchai Leelakusolvong, Chainarong Phalanusitthepa

    Background/Aims: Achalasia is an esophageal motility disorder. Peroral endoscopic myotomy is widely used for all subtypes; however, randomized head-to-head evidence comparing the anterior and posterior approaches remains limited. We compared efficacy, safety, and reflux outcomes.Methods: We conducted a single-center, single-blind, prospective randomized controlled trial from February 2023 to August 2024. Twenty-eight patients with achalasia types I–III were randomized to anterior or posterior peroral endoscopic myotomy. The primary outcomes were esophageal acid exposure at 3 months (24-hour pH monitoring) and clinical success (Eckardt score ≤3). The secondary outcomes were procedural parameters, complications, timed barium esophagography, manometry, and reflux esophagitis.Results: Baseline characteristics were comparable between the groups. Procedural metrics and complication rates were similar and mild, with no severe adverse events. At 12 months, both groups showed significant symptom relief, reduced Eckardt scores, and decreased lower esophageal sphincter pressure. Posterior myotomy yielded a higher proportion of abnormal DeMeester scores (57.1% vs. 28.6%, p=0.14), although reflux esophagitis remained mild and comparable between the groups.Conclusions: Posterior peroral endoscopic myotomy demonstrated comparable efficacy, safety, and reflux outcomes. The anterior approach improved clearance on timed barium esophagography; however, both approaches achieved durable symptom control with acceptable safety profiles, supporting posterior myotomy as a valid alternative.


  • Open Access

    Diagnostic Performance of 6 Tests for Helicobacter pylori Infection in Peptic Ulcer Bleeding: A Prospective Head-to-Head Comparison

    by Tanawat Geeratragool, Thanapat Atthakitmongkol, Supathep Tansirichaiya, Pubet Weeranawin, Somchai Leelakusolvong, Monthira Maneerattanaporn

    INTRODUCTION: Rapid urease test (RUT) is widely used for diagnosing Helicobacter pylori (HP) because it is inexpensive and practical. However, its accuracy is reduced in peptic ulcer bleeding (PUB). We prospectively performed a head-to-head comparison of diagnostic tests in the same patients to evaluate their performance in this setting. METHODS: After endoscopic hemostasis, gastric biopsies were obtained for RUT, histology, and polymerase chain reaction (PCR). Blood samples were collected for current infection marker and antiurease antibody. Urea breath testing (UBT) was performed in patients with negative RUT and histology. Diagnostic performance was assessed using a composite reference standard defined by at least 2 positive results among RUT, histology, PCR, and UBT. Logistic regression was used to identify factors associated with false-negative RUT. RESULTS: A total of 135 patients with PUB were enrolled, of whom 36 (26.7%) were HP-positive. Sensitivity/specificity was 69.4%/97.0% for RUT, 55.6%/96.0% for histology, 97.2%/92.9% for PCR, 77.8%/77.8% for current infection marker, and 83.3%/62.6% for antiurease antibody. Combining RUT, histology, and either PCR or UBT increased sensitivity to 100% and significantly outperformed RUT alone ( P = 0.021 and P = 0.001, respectively). PCR reduced idiopathic ulcers from 31.9% to 26.7%. Only 43 of 98 patients with negative RUT and histology underwent UBT because of clinical constraints, limiting its practicality despite excellent performance. No predictors of false-negative RUT were identified. DISCUSSION: In PUB, tissue PCR showed the best overall diagnostic performance among the single tests. RUT alone is insufficient for diagnosing HP, whereas combined testing with RUT, histology, and PCR or UBT achieved the highest diagnostic performance.


  • Open Access

    Proton Pump Inhibitors Prescribing Behaviors and Rationalization Strategies Among Healthcare Providers in Southeast Asia

    by Duc Trong Quach, Tien Manh Huynh, Augusto Jose G. Galang, Hang Viet Dao, Sakkarin Chirapongsathorn, Phuripong Kijdamrongthum, Rahela Ambaras Khan, Andrew Ming‐Liang Ong, Wee Kooi Cheah, Kalwinder Singh Khaira, et al.

    Despite widespread use, real‐world evidence regarding proton pump inhibitor (PPI) prescribing and rationalization practices in Southeast Asia (SEA) remains limited; therefore, we aimed to characterize current prescribing behaviors and rationalization strategies among healthcare professionals in the region. The SEA PPI Rationalisation Working Group developed and disseminated an online questionnaire via professional networks across SEA to collect data on respondent demographics, PPI prescribing practices, and rationalization approaches; instrument reliability testing produced a Cronbach's α of 0.799 and content validity was confirmed by a panel of 10 gastroenterology experts with complete agreement on relevance and clarity (I‐CVI, kappa, SCVI/Ave = 1.0). K‐mode clustering was applied to delineate prescribing patterns. Of 869 responses received, 763 valid entries were analyzed (response rate 87.8%), 49% of whom were gastroenterologists. PPIs were most frequently prescribed for gastroesophageal reflux disease (67.8%) and peptic ulcer disease (43.8%); 48.9% of respondents reported long‐term PPI use, while 59.2% reported reassessment of indications at every follow‐up visit. Common rationalization strategies comprised dose tapering (46.8%), on‐demand administration (45.9%), and step‐down to antacids or alginates (44.8%). Cluster analysis identified two distinct prescriber profiles: proactive prescribers ( n = 326, 42.7%), who adhered to clinical guidelines, implemented individualized dosing, and routinely reassessed therapy; and conservative prescribers ( n = 437, 57.3%), who employed PPIs more restrictively and engaged less frequently in rationalization. The considerable variability in PPI prescribing and rationalization practices across SEA underscores the need for a regional consensus to promote evidence‐based practice.

  • Open Access

    Rationalizing Proton Pump Inhibitor Use: Southeast Asia Consensus Recommendations

    by Somchai Leelakusolvong, Tju Siang Chua, Duc Trong Quach, Andrew Ming‐Liang Ong, Ari Fahrial Syam, Augusto Jose G. Galang, Wee Kooi Cheah, Hang Viet Dao, Jose D. Sollano, Kalwinder Singh Khaira, et al.

    Background and Aim: Proton pump inhibitors (PPIs) are integral to managing many gastrointestinal conditions. However, the prevalent inappropriate PPI prescription across Southeast Asia (SEA) is concerning. Given the absence of locally tailored recommendations to inform clinical practice, this consensus document aims to provide recommendations for PPI rationalization to healthcare providers in the region. Methods: The SEA PPI Rationalization Working Group is steered by 14 experts practicing across Malaysia, Thailand, Singapore, Vietnam, the Philippines, and Indonesia. The experts convened to review existing evidence and develop recommendations and to conduct an anonymous voting as per the modified Delphi method. Results: Twenty statements were formulated, focusing on areas of (i) extent and impact of PPI overprescription (four statements), (ii) benefits and barriers to PPI rationalization (two statements), (iii) START/STOPP criteria for PPI (nine statements), and (iv) PPI rationalization strategies (five statements). The consensus document underscores the widespread inappropriate long‐term PPI prescription across SEA, which may have adverse clinical outcomes. Although rationalizing PPI use may be beneficial, the experts acknowledge the challenges of implementing PPI rationalization. The experts also outlined specific indications to guide PPI initiation and advised regular review to rationalize a PPI when no longer indicated. This is followed by PPI rationalization strategies, including shared decision‐making, prescribing alginate as a rescue therapy in gastroesophageal reflux disease, and further evaluation for reinitiation of PPI when clinically warranted. Conclusions: This consensus document serves to improve PPI prescribing and deprescribing practices in SEA and to provide recommendations on rationalization strategies.


  • Open Access

    Proton Pump Inhibitors Prescribing Behaviors and Rationalisation Strategies among Healthcare Providers in the Southeast Asia

    by Duc Trong Quach, Tien Manh Huynh, Augusto Jose G. Galang, Hang Viet Dao, Sakkarin Chirapongsathorn, Phuripong Kijdamrongthum, Rahela Ambaras Khan, Andrew Ming-Liang Ong, Wee Kooi Cheah, Kalwinder Singh Khaira, et al.

    SUMMARY: Background: Despite its widespread use, real-world evidence on proton pump inhibitor (PPI) prescribing and rationalisation practices in Southeast Asia (SEA) remains limited. This study aimed to investigate current prescribing behaviors and rationalisation strategies among SEA healthcare professionals. Methods: The SEA PPI Rationalisation Working Group designed and disseminated an online survey across SEA via professional networks. The questionnaire included sections on demographics, PPI prescribing habits, and rationalisation strategies. Reliability testing of the questionnaire yielded a Cronbach’s alpha of 0.799. Content validity was confirmed by a panel of 10 gastroenterology experts, with perfect agreement on relevance and clarity (I-CVI, kappa, SCVI/Ave = 1.0). K-mode clustering was used to explore prescribing patterns. The main outcome was the identification of prescribing patterns and rationalisation strategies for long-term PPI use. Findings: Among the 869 responses received, 763 valid entries were analysed (response rate: 87.8%), with 49% of the respondents being gastroenterologists. PPIs were most prescribed for gastroesophageal reflux disease (67.8%) and peptic ulcer disease (43.8%). Long-term PPI use was reported by 48.9% of the participants, while 59.2% reported reassessing indications at every follow-up visit. Rationalisation strategies included dose tapering (46.8%), on-demand use (45.9%), and step-down to antacids or alginates (44.8%). Cluster analysis identified two profiles: proactive prescribers (n=326, 42.7%) who followed clinical guidelines, applied individualised dosing, and routinely reassessed therapy, and conservative prescribers (n=437, 57.3%) who used PPIs more restrictively and rationalised less frequently. Interpretation: Marked variability in PPI prescribing and rationalisation across SEA highlights the need for regional consensus to support evidence-based practice. Funding: This study was supported by Reckitt Benckiser (Singapore) Pte Ltd ., which provided funding for article processing charge Evidence before this study: Although proton pump inhibitors (PPIs) are widely prescribed across Southeast Asia (SEA), there is limited real-world evidence examining the prescribing behaviors and rationalisation practices within the region. Previous research predominantly focused on Western countries and raised concerns regarding the over-prescription and prolonged use of PPIs. However, no studies have comprehensively addressed the regional variability in PPI prescribing or the strategies employed to rationalise their use in SEA. Added value of this study: This study provides the first region-wide analysis of PPI prescribing practices and rationalisation strategies in SEA. By employing cluster analysis, the study identifies two distinct prescriber profiles: proactive prescribers, who follow clinical guidelines and individualise treatment, and conservative prescribers, who use PPIs more restrictively and apply rationalisation strategies less frequently. The study offers critical insights into the current prescribing landscape in SEA, highlighting the need for evidence-based regional guidelines to optimise PPI use. Implications of all the available evidence: The findings suggest that significant variability in PPI prescribing exists across SEA, underscoring the necessity for region-specific guidelines. Policymakers should use these insights to inform evidence-based clinical guidelines for PPI use and rationalisation. Additionally, future research should explore the effectiveness of rationalisation strategies and identify barriers to their implementation within diverse healthcare systems in SEA.


  • Role of Prucalopride in the Treatment of Chronic Constipation in Parkinson Disease: A Randomized Controlled Trial

    by Nutchanun Preechakawin, Monthira Maneerattanaporn, Tanawat Geeratragool, Prachaya Srivanitchapoom, Yuvadee Pitakpatapee, Somchai Leelakusolvong

    INTRODUCTION: Constipation, a prevalent nonmotor symptom in Parkinson disease (PD), adversely affects patients' quality of life. Prucalopride, a selective serotonin type 4 receptor agonist, has shown efficacy as a treatment of functional constipation, but its role in PD-related constipation remains underexplored. The objective of this study was to assess the efficacy, safety, and quality-of-life impact of prucalopride in PD patients with chronic constipation. METHODS: In this double-blind randomized controlled trial, PD patients with chronic constipation received prucalopride (2 mg) or placebo once daily for 8 weeks. The primary outcome was the change in the number of spontaneous bowel movements (SBMs) per week from baseline to week 8. Secondary outcomes included stool consistency, straining, and changes in Patient Assessment of Constipation-Symptoms and Patient Assessment of Constipation-Quality of Life scores. Parkinsonian motor severity was assessed using the Unified Parkinson Disease Rating Scale. RESULTS: Fifty-seven patients were included (prucalopride = 30, placebo = 27). At week 8, the change in the number of weekly SBMs was significantly larger in the prucalopride group (3.2 ± 2.8) than in the placebo group (1.6 ± 1.9; P = 0.02). Longitudinal analysis confirmed a significantly higher SBM frequency in the prucalopride group throughout the 8-week period ( P = 0.015). Secondary outcomes showed trends toward improvement but no statistically significant differences. No serious adverse events were reported, and Unified Parkinson Disease Rating Scale scores remained unchanged. DISCUSSION: Prucalopride was safe, well-tolerated, and more effective than placebo in increasing bowel movement frequency in PD patients with chronic constipation, supporting its potential as a therapeutic option in this population.


  • Open Access

    Timed barium esophagography to predict recurrent achalasia after peroral endoscopic myotomy: a retrospective study in Thailand

    by Tharathorn Suwatthanarak, Chainarong Phalanusitthepa, Chatbadin Thongchuam, Thawatchai Akaraviputh, Vitoon Chinswangwatanakul, Thikhamporn Tawantanakorn, Somchai Leelakusolvong, Monthira Maneerattanaporn, Piyaporn Apisarnthanarak, Jitladda Wasinrat

    Background/Aims: Achalasia is a rare esophageal motility disease, for which peroral endoscopic myotomy (POEM) has emerged as a promising treatment option; however, recurrence remains a challenge. Timed barium esophagography (TBE) is a useful diagnostic tool and potential outcome predictor of achalasia. This study aimed to determine predictive tools for recurrence after POEM.Methods: This retrospective study enrolled achalasia patients who underwent POEM between January 2015 and December 2021. Patients were categorized into two groups using the 1-month post-POEM Eckardt scores and TBE: the discordant group (Eckardt score improved >50%, TBE decreased 50%). Recurrence was defined as a reincrease in the Eckardt score to more than three during follow-up.Results: Complete medical records were available in 30 patients who underwent POEM. Seventeen patients (56.7%) were classified into the discordant group, while 13 patients (43.3%) were in the concordant group. The overall recurrence rate was 11.9% at 1-year, increasing to 23.8% during the extended follow-up. The discordant group had a 6.87 fold higher recurrence rate than the concordant group (52.9% vs. 7.7%, p=0.017).Conclusions: These results strongly suggest that combining the Eckardt score with TBE can effectively predict recurrent achalasia after POEM. Patients in the discordant group had an elevated risk.


  • Open Access

    The Performance of Peroral Endoscopic Myotomy in Sigmoid-Type Achalasia

    by Chainarong Phalanusitthepha, Siwaree Maneesoi, Jirawat Watthanatha, Tharathorn Suwatthanarak, Vitoon Chinswangwatanakul, Thawatchai Akaraviputh, Asada Methasate, Monthira Maneerattanaporn, Somchai Leelakusolvong

    Objective: Sigmoid-type achalasia represents an advanced stage of achalasia characterized by significant dilation and tortuosity of the esophageal lumen. Considering the demonstrated efficacy of peroral endoscopic myotomy (POEM) in treating early-stage achalasia, this procedure may offer an alternative therapeutic approach for sigmoid-type achalasia. This study aimed to assess POEM’s feasibility and short-term efficacy in patients with sigmoid-type achalasia. Materials and Methods: We enrolled 16 consecutive patients with sigmoid-type achalasia (eight with type 1 and eight with type 2). The anticipated outcomes were symptom relief during the 12-month follow-up period (evaluated through a reduction in Eckardt symptom scores), an acceptable incidence of procedure-related adverse events, and a decrease in esophageal diameter and barium height. Results: POEM was successfully performed in all cases, with a median operative time of 118.50 minutes (range: 52–206 minutes). No serious complications associated with POEM were observed. During the 12-month follow-up period, the median Eckardt symptom score decreased from 6 (2-10) preoperatively to 1 (0-3) (P = 0.008). Complications were mucosal injuries (31.25% of cases), pneumoperitoneum (12.5%), and minor bleeding (6.25%), although no interventions were needed. Conclusion: POEM procedure has exhibited favorable treatment outcomes, showcasing a high clinical success rate in addressing sigmoid-type achalasia. Despite the occurrence of acceptable adverse events, the procedure remains a viable alternative treatment or bridging therapy for sigmoid-type achalasia. Nonetheless, it is crucial to acknowledge that this procedure presents greater challenges in comparison to the treatment of typical achalasia.

  • 614 COMPARISON OF VONOPRAZAN VERSUS INTRAVENOUS PROTON PUMP INHIBITORS FOR PREVENTION OF HIGH-RISK PEPTIC ULCERS REBLEEDING AFTER SUCCESSFUL ENDOSCOPIC HEMOSTASIS; A RANDOMIZED NON-INFERIORITY TRIAL

    by Tanawat Geeratragool, Uayporn Kaosombatwattana, Arpapun Boonchote, Suvikrom Chattammanat, Nutchanun Preechakawin, Jompol Srichot, Asawin Sudcharoen, Pavapol Sirisunhirun, Panotpol Termsinsuk, Manus Rugivarodom, et al.